Manager TitleAgeSince
President - 2023-12-13
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 2023-12-13
Director/Board Member - 2023-12-13
Date Insider Type Main position Quantity % Market Cap.
23-12-13Issuer sale

Director

127,934 0.0678%
23-12-13Issuer sale

Director

97,934 0.0519%
23-12-13Issuer sale

Executive/Senior Manager

225,162 0.1193%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
+1.08%+7.56%+3.61%+9.84% 50.25B
+0.40%-1.37%+401.69%+625.15% 40.39B
-0.52%+6.57%+25.41%-5.37% 34.38B
+3.97%+6.71%+26.06%+63.36% 34.4B
-4.19%-1.84%+3.76%+32.17% 26.32B
-2.40%+1.60% - - 16.64B
+1.34%+5.68%+75.77%+141.51% 16.14B
-0.95%+0.76%+12.92%+21.59% 13.71B
+1.69%+3.09%+93.44%+99.19% 13.75B
Average +0.04%+3.57%+80.33%+123.43% 27.33B
Weighted average by Cap. +0.23%+4.03%+91.39%+141.84%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock